To determine if HER2-BsAb retained the specificity of trastuzumab, the HER2(+)high SKOV3 ovarian carcinoma cell line was pre-incubated with 10 μg/mL of trastuzumab for 30 min and then immunostained using 1 μg/mL HER2-BsAb labeled with Alexa 488 (Fig. 1A). This evidence concerns the gene ERBB2 and ovarian carcinoma.